PASPORT Rare Tumors is a clinical trial, within the PASPORT clinical trial research program, to evaluate pasireotide for the treatment of a group of rare neuroendocrine tumors arising in the pituitary, pancreas, gastrointestinal tract, or ectopic locations.
At least 18 years of age with confirmed
Rare pituitary, pancreatic, or gastroenteric neuroendocrine tumors
Ectopic ACTH-secreting tumors
Failed standard of care or no standard of care is available
ECOG performance status <=2
Patients with any ongoing or planned antineoplastic or interferon therapy
Patients with active gallbladder disease
Patients treated with radiolabeled somatostatin analogue therapy within the last 6 months, cytotoxic or interferon therapy within the last 2 months, or radiotherapy within the last month
To find out more about this rare tumors clinical trial, Click here
Disclaimer: This is a global web site for Pasport™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain program information that is different from where you practice. Please contact your local Novartis representative for the latest information specific to your country.